Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the December 2024 edition of ZERO’s Prostate Cancer Discoveries Digest! The latest information on treatment, outcomes, and health equity has been pulled from the headlines and delivered to your inbox. To make sure you receive this monthly newsletter, be sure to add ZERO Prostate Cancer to your contact list. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Treatment FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research New research assessing the safety and effectiveness of an investigational new drug will begin in early 2025. This drug helps identify cancer tissue more precisely and helps surgeons distinguish cancerous from non-cancerous tissue during surgery and PET scans. » Full Article from Targeted Oncology Health Equity Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA In one of the largest cohort studies in prostate cancer epidemiology to date, findings provide data on incidence rates, prevalence, and progression rates across prostate cancer disease states by race and ethnicity within the Veterans Health Administration. » Full Article at JAMA Network Outcomes MRI-Guided SBRT Reduces Side Effects in Prostate Cancer Treatment Results of the MIRAGE trial provide a comprehensive two-year follow-up, finding that MRI-guided SBRT for prostate cancer significantly reduced long-term side effects and improved quality of life, specifically in bowel function and sexual health, when compared to conventional CT-guided treatment. » Full Article from News-Medical Treatment Reduction of Myeloid-Derived Suppressor Cells in Prostate Cancer Murine Models and Patients Following White Button Mushroom Treatment A paper published in Clinical and Translational Medicine indicated that white button mushroom extract may help slow the progression of prostate cancer. » Full Article from Wiley Online Library Treatment Progression-Directed Therapy in Oligoprogressive Castration-Resistant Prostate Cancer PDT could postpone the need for next-line systemic treatment in these patients with so-called oligoprogressive mCRPC. » Full Article at UroToday Outcomes Study Indicates Overtreatment of Men with Prostate Cancer and Limited Life Expectancy Findings from a recent cohort study of 243,928 patients with clinically localized prostate cancer in the VA health system indicate that those with intermediate- to high-risk prostate cancer and limited life expectancy may be increasingly overtreated. » Full Article from Urology Times Treatment AZ's Truqap Delivers Phase 3 Win in Prostate Cancer Subtype After Recent Breast Cancer Miss AstraZeneca’s high-level results from an ongoing phase 3 trial demonstrated that a combination of Truqap, Zytiga, and androgen deprivation therapy delivered statistically significant and clinically meaningful improvements on the primary endpoint of radiographic progression-free survival. » Full Article from Fierce Pharma Treatment FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer The FDA has accepted a supplemental new drug application seeking the approval of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). » Full Article at OncLive ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the December 2024 edition of ZERO’s Prostate Cancer Discoveries Digest! The latest information on treatment, outcomes, and health equity has been pulled from the headlines and delivered to your inbox. To make sure you receive this monthly newsletter, be sure to add ZERO Prostate Cancer to your contact list. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Treatment FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research New research assessing the safety and effectiveness of an investigational new drug will begin in early 2025. This drug helps identify cancer tissue more precisely and helps surgeons distinguish cancerous from non-cancerous tissue during surgery and PET scans. » Full Article from Targeted Oncology Health Equity Racial and Ethnic Differences in Prostate Cancer Epidemiology Across Disease States in the VA In one of the largest cohort studies in prostate cancer epidemiology to date, findings provide data on incidence rates, prevalence, and progression rates across prostate cancer disease states by race and ethnicity within the Veterans Health Administration. » Full Article at JAMA Network Outcomes MRI-Guided SBRT Reduces Side Effects in Prostate Cancer Treatment Results of the MIRAGE trial provide a comprehensive two-year follow-up, finding that MRI-guided SBRT for prostate cancer significantly reduced long-term side effects and improved quality of life, specifically in bowel function and sexual health, when compared to conventional CT-guided treatment. » Full Article from News-Medical Treatment Reduction of Myeloid-Derived Suppressor Cells in Prostate Cancer Murine Models and Patients Following White Button Mushroom Treatment A paper published in Clinical and Translational Medicine indicated that white button mushroom extract may help slow the progression of prostate cancer. » Full Article from Wiley Online Library Treatment Progression-Directed Therapy in Oligoprogressive Castration-Resistant Prostate Cancer PDT could postpone the need for next-line systemic treatment in these patients with so-called oligoprogressive mCRPC. » Full Article at UroToday Outcomes Study Indicates Overtreatment of Men with Prostate Cancer and Limited Life Expectancy Findings from a recent cohort study of 243,928 patients with clinically localized prostate cancer in the VA health system indicate that those with intermediate- to high-risk prostate cancer and limited life expectancy may be increasingly overtreated. » Full Article from Urology Times Treatment AZ's Truqap Delivers Phase 3 Win in Prostate Cancer Subtype After Recent Breast Cancer Miss AstraZeneca’s high-level results from an ongoing phase 3 trial demonstrated that a combination of Truqap, Zytiga, and androgen deprivation therapy delivered statistically significant and clinically meaningful improvements on the primary endpoint of radiographic progression-free survival. » Full Article from Fierce Pharma Treatment FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer The FDA has accepted a supplemental new drug application seeking the approval of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). » Full Article at OncLive ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to take the place of medical professionals or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
